Guidelines of the Brazilian Society of Surgical Oncology for anatomopathological, immunohistochemical, and molecular testing in female tumors
Authors:
- Reitan RibeiroRRReitan Ribeiro
- Filomena Marino CarvalhoFCFilomena Marino Carvalho
- Glauco BaiocchiGBGlauco Baiocchi
- Carlos Henrique dos AnjosCACarlos Henrique dos Anjos
- Renato Cagnacci NetoRNRenato Cagnacci Neto
- Allyne Queiroz Carneiro CagnacciACAllyne Queiroz Carneiro Cagnacci
- Vandré Cabral Gomes CarneiroVCVandré Cabral Gomes Carneiro
- Aknar CalabrichACAknar Calabrich
- 22 July 2024
- journal article
- review article
- Published by Wiley in Journal of Surgical Oncology
- Vol. 130 (4) , 882-895
Abstract
Introduction: Precision medicine has revolutionized oncology, providing more personalized diagnosis, treatment, and monitoring for patients with cancer. In the context of female‐specific tumors, such as breast, ovarian, endometrial, and cervical cancer, proper tissue collection and handling are essential for obtaining tissue, immunohistochemical (IHC), and molecular data to guide therapeutic decisions.Objectives: To establish guidelines for the collection and handling of tumor tissue, to enhance the quality of samples for histopathological, IHC, genomic, and molecular analyses. These guidelines are fundamental in informing therapeutic decisions in cancer treatment.Method: The guidelines were developed by a multidisciplinary panel of renowned specialists between June 12, 2013 and February 12, 2024. Initially, the panel deliberated on critical and controversial topics related to conducting precision medicine studies focusing on female tumors. Subsequently, 22 pivotal topics were identified within the framework and assigned to groups. These groups reviewed relevant literature and drafted preliminary recommendations. Following this, the recommendations were reviewed by the coordinators and received unanimous approval. Finally, the groups made the final adjustments, classified the level of evidence, and ranked the recommendations.Conclusion: The collection of surgical samples requires minimum quality standards to enable histopathological, IHC, genomic, and molecular analyses. These analyses provide crucial data for informing therapeutic decisions, significantly impacting potential survival gains for patients with female tumors.Keywords
Funding Information
- AstraZeneca
- GlaxoSmithKline
This publication has 115 references indexed in Scilit:
- FIGO staging of endometrial cancer: 2023International Journal of Gynecology & Obstetrics, 2023
- PARP Inhibitors in Ovarian Cancer: A ReviewTargeted Oncology, 2023
- Cancer risk‐reducing surgery: Brazilian society of surgical oncology guideline part 1 (gynecology and breast)Journal of Surgical Oncology, 2022
- Endometrial cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-upAnnals of Oncology, 2022
- ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancerAnnals of Oncology, 2021
- Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021Annals of Oncology, 2021
- Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working GroupAnnals of Oncology, 2020
- Human papillomavirus in cervical cancer and oropharyngeal cancer: One cause, two diseasesCancer, 2017
- Serum HER‐2/neu conversion to positive at the time of disease progression in patients with breast carcinoma on hormone therapyCancer, 2005
- Comparison of HER‐2 status determined by fluorescence in situ hybridization in primary and metastatic breast carcinomaCancer, 2005